Does pharmacological stimulation of NADH oxidation ameliorate obesity and related phenotypes in mice?
Pharmacological activation of NADH oxidation by NQO1 resolves obesity and related phenotypes in mice, opening the possibility that it may provide the basis for a new therapy for the treatment of metabolic syndrome.
Insulin-like growth factor type I does not provide benefit for patients with amyotrophic lateral sclerosis.